In 60 patients with newly diagnosed myeloma having autologous transplant, Evomela 200 or 225 mg/m2 by short or long infusion caused no grade ≥4 non-haematological toxicity or day-100 non-relapse deaths; secondary MRD-negative CR was 43% vs 47% by schedule.
RCTn = 60
Bashir et al. Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200